India Unveils Indigenous Gene Therapy for Sickle Cell Disease

 



India has launched its first indigenous CRISPR-based gene therapy for Sickle Cell Disease, marking a landmark moment for national genomic medicine and tribal healthcare. The therapy, named BIRSA 101 in honour of Birsa Munda, strengthens the country’s position in advanced therapeutic innovation.

Breakthrough Launch and Scientific Significance

Unveiled by the Union Minister of State for Science and Technology, the therapy represents a major milestone in the Atmanirbhar Bharat initiative. It uses precise gene-editing technology to correct the defective gene responsible for Sickle Cell Disease. The innovation is designed to serve as a long-term curative solution for hereditary blood disorders.

Burden of Sickle Cell Disease in India

Sickle Cell Disease severely impacts tribal regions across central and eastern India. It causes chronic anaemia, painful crises and progressive organ damage. The therapy aims to support national efforts to reduce the burden of the disorder, particularly among underserved communities with limited access to advanced medical care.

Development, Affordability and Public-Private Collaboration

Developed by the CSIR-Institute of Genomics and Integrative Biology, the therapy showcases India’s ability to deliver high-end medical solutions at a fraction of global prices. A collaboration agreement with a leading vaccine and biotech manufacturer will enable large-scale production. This partnership supports the transition of the enFnCas9 CRISPR platform into widely available, low-cost therapies for multiple genetic disorders.

National Mission and Future Health Impact

The launch advances the goal of a Sickle Cell–free India by 2047. Integrated with nationwide screening and prevention programmes across tribal districts, the therapy provides a pathway to accessible, curative treatment. Its development establishes India as a leader in developing advanced, affordable genetic technologies for vulnerable populations.

#GeneTherapy
#GeneticMedicine
#GenomeEditing
#CRISPRTechnology
#CellAndGeneTherapy
#MolecularMedicine
#BiomedicalInnovation
#FutureOfMedicine
#GeneticResearch
#TherapeuticGenomics

World Cell Biologist Awards: 

Website Link : cellbiologist.org 

Follow Us On : 
Tumblr ; tumblr.ccom/

Comments

Post a Comment

Popular posts from this blog

Uttrakhand Forest Department Establishes Mahabharata Vatika

Image
  The Uttarakhand Forest Department has established two gardens in Haldwani, showcasing plant species referenced in ancient Indian epics. These gardens, named Ramayana Vatika and Mahabharata Vatika, aim to highlight the ecological wisdom embedded in these texts. Mahabharata Vatika Overview Mahabharata Vatika spans one acre and features 37 plant species mentioned in the epic. Chief Conservator of Forests Sanjeev Chaturvedi emphasised the research behind selecting these species. The garden features important plant species such as: Ecological Significance The garden puts stress on the importance of forests as depicted in the Mahabharata. It references the Vana Parva, which discusses tree planting and wildlife conservation . The epic highlights the mutual dependence of tigers and forests, a concept vital to contemporary conservation efforts. Cultural Connections Chaturvedi brought into light that the Mahabharata teaches the spiritual significance of planting trees. He mentioned Bhish...
Read more

What is Zolgensma?

Image
  Spinal Muscular Atrophy (SMA) is a rare genetic disease affecting muscle function. In India, treatment options are limited, mainly due to high costs. The gene therapy drug, Zolgensma , costs around 16 crore rupees. Despite this, some families are finding ways to access treatment. About Spinal Muscular Atrophy (SMA) SMA is a genetic disorder that leads to the loss of motor neurons in the spinal cord. This results in muscle weakness and atrophy. Symptoms often appear in infancy. Children may struggle with basic movements like lifting their heads or crawling. Early diagnosis is crucial for effective treatment. About Zolgensma Zolgensma (onasemnogene abeparvovec-xioi) is a revolutionary gene therapy for SMA. It addresses the root cause by replacing the missing or defective SMN1 gene . This therapy can improve motor function in affected children. Although it is costly, it represents hope for many families. SMA is not as rare as once thought. The global prevalence is estimated at 1 in ...
Read more

CAR T-Cell Therapy for Cancer

Image
  India has recently made strides in cancer treatment with the introduction of CAR T-cell therapy . The results from the first clinical trials have been published in The Lancet, showcasing a remarkable success rate. This therapy is a game changer for patients with blood cancers. It offers hope to those who have exhausted other treatment options. What is CAR T-Cell Therapy? CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an innovative treatment that harnesses the body’s immune system. It trains T-cells to target and destroy cancer cells. This therapy is specifically designed for certain blood cancers. It is particularly beneficial for patients whose cancer has relapsed or failed to respond to standard treatments. Clinical Trial The clinical trials reported a response rate of nearly 73%. This indicates that number of patients benefited from the treatment. The trials also provided critical data on survival rates for patients with acute lymphoblastic leukaemia and l...
Read more